Broad-Spectrum Antiviral Peptides Explained

Antiviral Peptides

4 mechanisms

Antiviral peptides fight viruses through membrane disruption, fusion inhibition, receptor blocking, and immune modulation, often targeting multiple virus families simultaneously.

Mashhadi et al., Virus Research, 2025

Mashhadi et al., Virus Research, 2025

View as image

Most antiviral drugs target a single protein on a single virus. When that virus mutates, the drug stops working. Broad-spectrum antiviral peptides take a fundamentally different approach: they exploit structural features shared across entire virus families, most commonly the lipid membrane envelope that surrounds many pathogenic viruses. Because lipid membranes cannot mutate the way proteins can, peptides that disrupt viral envelopes face a lower barrier to resistance development than conventional antivirals.^[1]

This is the central promise and the central challenge. As part of the broader family of antiviral peptide compounds explored in the cyclotides research, broad-spectrum antiviral peptides (AVPs) have demonstrated activity against influenza, coronaviruses, HIV, herpes simplex, dengue, and Ebola-family viruses in laboratory studies. Only one antiviral peptide, enfuvirtide (Fuzeon), has reached FDA approval, and it targets a single virus (HIV-1) through a specific fusion inhibition mechanism rather than broad-spectrum membrane disruption.

Four Ways Peptides Fight Viruses

A 2025 review by Mashhadi and colleagues in Virus Research categorized antiviral peptide mechanisms into four classes, each targeting a different stage of the viral life cycle:^[1]

1. Viral envelope disruption. Cationic amphiphilic peptides insert into the lipid bilayer of enveloped viruses, creating pores or physically disintegrating the membrane. This is the most direct mechanism: the virus is physically destroyed before it contacts a host cell. It works against any enveloped virus (influenza, coronaviruses, HIV, HSV, dengue, Ebola) but cannot affect non-enveloped viruses (norovirus, poliovirus, adenovirus) that lack a lipid membrane.

2. Fusion inhibition. Some peptides mimic regions of viral fusion proteins, competitively blocking the conformational changes required for the virus to merge with host cell membranes. EK1 exemplifies this approach: it targets the HR1 domain of coronavirus spike proteins to prevent the six-helix bundle formation that drives membrane fusion.

3. Receptor blocking. Peptides can bind viral surface proteins and physically occlude the receptor-binding sites that viruses use to attach to host cells. LL-37's interaction with the SARS-CoV-2 spike protein operates through this mechanism.

4. Host immune modulation. Rather than attacking the virus directly, some peptides enhance the host's antiviral immune response by stimulating interferon production, activating natural killer cells, or promoting dendritic cell maturation. This mechanism is harder to study because the effects are indirect and context-dependent.

Most broad-spectrum antiviral peptides use mechanism 1 (envelope disruption) as their primary mode of action, with mechanisms 3 and 4 contributing secondarily. Fusion inhibitors (mechanism 2) tend to be more virus-specific because they target particular protein structures.

Membrane-Disrupting Peptides: The Original Broad-Spectrum Approach

Cationic Amphiphilic Peptides vs. Multiple Viruses

Albiol Matanic and colleagues published one of the foundational studies of cationic peptide antiviral activity in 2004, testing five structurally diverse antimicrobial peptides against two unrelated virus families: Junin virus (an arenavirus causing Argentine hemorrhagic fever) and herpes simplex virus types 1 and 2 (herpesviruses).^[2]

The results demonstrated genuine broad-spectrum activity:

• Cecropin A (insect-derived, alpha-helical): effectively inhibited all three viruses
• Melittin (bee venom, alpha-helical): active against both Junin and HSV, though with higher cytotoxicity
• Magainin I and II (frog-derived, alpha-helical): showed antiviral activity with lower toxicity profiles
• Indolicidin (bovine neutrophil, tryptophan-rich): active against HSV

The cross-family activity, working against both an arenavirus and herpesviruses, is the hallmark of membrane-targeting rather than protein-targeting activity. Junin virus and herpes simplex share almost no protein homology, but both have lipid envelope membranes susceptible to amphiphilic peptide disruption.

The therapeutic challenge is selectivity. Melittin, despite potent antiviral activity, also damages host cell membranes at similar concentrations, creating a narrow therapeutic window. For a detailed analysis of melittin's mechanism and selectivity challenges, see Melittin: How Bee Venom Peptide Disrupts Virus Membranes.

Cathelicidins: LL-37 and Beyond

Human cathelicidin LL-37 is the only cathelicidin antimicrobial peptide produced in the human body, and it has demonstrated antiviral activity across multiple virus families. Its expression is regulated by vitamin D, creating the molecular basis for the vitamin D-antimicrobial peptide connection.

Roth and colleagues (2025) demonstrated that LL-37 binds directly to the SARS-CoV-2 spike protein and blocks its interaction with the ACE2 receptor on host cells.^[3] This receptor-blocking mechanism (mechanism 3) works alongside LL-37's established membrane-disrupting activity, giving the peptide two independent modes of antiviral action against SARS-CoV-2.

Cerps and colleagues (2025) showed that LL-37 increases rhinovirus-induced interferon-beta expression, demonstrating the immune modulation mechanism (mechanism 4).^[4] Rather than killing rhinovirus directly, LL-37 amplified the host's own antiviral signaling cascade. This is an indirect route to antiviral activity that may be particularly relevant for non-enveloped viruses that resist membrane disruption.

Deng and colleagues (2026) expanded the cathelicidin antiviral story beyond LL-37 by testing a peptide derived from hedgehog cathelicidin against herpes simplex virus type 1. The hedgehog-derived peptide showed direct antiviral activity, suggesting that cathelicidins across mammalian species carry antiviral functions that can be exploited therapeutically.^[5]

Fusion Inhibitors: Targeted Broad-Spectrum Activity

EK1C4: One Peptide Against Coronaviruses and HIV

The most striking example of engineered broad-spectrum antiviral peptide activity is EK1C4, developed by Xia and colleagues (2020). EK1C4 is a lipopeptide that targets the HR1 domain of coronavirus spike proteins, blocking the six-helix bundle formation required for virus-cell membrane fusion.^[6]

Against SARS-CoV-2 S protein-mediated cell-cell fusion, EK1C4 achieved an IC50 of 1.3 nM, making it one of the most potent peptide-based coronavirus inhibitors reported. Critically, EK1C4 also inhibited fusion mediated by spike proteins from SARS-CoV, MERS-CoV, and multiple other human and bat coronaviruses, demonstrating pan-coronavirus activity.

The breadth of EK1C4 was extended by Zhu and colleagues (2021), who demonstrated that this same peptide possessed potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus (SIV).^[7] The study identified a shared structural feature in the HR1 domains of coronavirus spike proteins and HIV gp41 that explains this cross-family activity. EK1C4 recognized a conserved coiled-coil architecture used by both virus families during membrane fusion, a structural target unlikely to mutate because it is essential for viral entry.

This cross-family activity, one peptide inhibiting both coronaviruses and HIV, illustrates the potential of targeting conserved fusion machinery rather than virus-specific surface proteins. For more on EK1's mechanism and development, see EK1: The Pan-Coronavirus Fusion Inhibitor.

Temporin-Derived Peptides: Dual-Mechanism Inhibitors

Zannella and colleagues (2026) used structure-guided design to develop temporin-derived peptides (originally from frog skin secretions) as dual-mechanism inhibitors of SARS-CoV-2.^[8] Surface plasmon resonance screening showed that temporin G, temporin L, and a non-hemolytic analog (Pro3-TL) bind the SARS-CoV-2 spike protein's receptor-binding domain. Simultaneously, these peptides disrupt viral membrane integrity through their amphiphilic structure.

This dual-mechanism approach, combining spike protein binding (mechanism 3) with membrane disruption (mechanism 1), provides two independent barriers the virus would need to overcome to develop resistance. The non-hemolytic analog Pro3-TL is particularly significant because it retained antiviral activity while reducing the toxicity to host red blood cells that limits many membrane-active peptides.

Moving Toward Clinical Translation

Intranasal Delivery: Meeting the Virus Where It Enters

Wang and colleagues (2026) demonstrated that an intranasal macrocyclic peptide inhibitor protected mice against lethal SARS-CoV-2 infection.^[9] This study is notable for two reasons: the macrocyclic peptide structure provides enhanced stability compared to linear peptides (resistance to proteolytic degradation in the nasal mucosa), and the intranasal route delivers the antiviral directly to the respiratory epithelium where SARS-CoV-2 initiates infection.

The route of administration matters enormously for antiviral peptides. Systemic injection exposes the peptide to rapid proteolytic degradation in blood and dilutes it across the entire body when the infection is localized to the respiratory tract. Intranasal delivery concentrates the peptide at the site of viral entry, achieving higher local concentrations at lower total doses.

Reynard and colleagues (2025) advanced a parallel delivery strategy: nebulized inhalation of fusion-inhibitory lipopeptides for respiratory virus infections.^[10] Nebulized delivery reaches deeper into the lung than nasal sprays, potentially treating both upper and lower respiratory tract infections.

The Resistance Question

Kiran and colleagues (2025) revisited the potential of natural antimicrobial peptides against emerging respiratory viruses, specifically examining whether viral resistance to membrane-disrupting peptides can develop.^[11] The theoretical advantage of membrane-targeting peptides is clear: a virus cannot mutate its lipid bilayer the way it mutates surface proteins. However, some enveloped viruses can alter their lipid composition to reduce peptide binding, and resistance through altered membrane fluidity or charge has been demonstrated in bacteria exposed to antimicrobial peptides. For more on the bacterial resistance question, see antimicrobial peptides as alternatives to antibiotics.

Whether viruses develop analogous resistance mechanisms under selective pressure from antiviral peptides is an open question with limited experimental data. The theoretical resistance barrier is higher than for protein-targeted drugs, but "higher" does not mean "impossible."

AI-Driven Peptide Design

The 2025 review by Mashhadi and colleagues highlighted the growing role of artificial intelligence in antiviral peptide development.^[1] Machine learning models, generative adversarial networks, and large language models are being applied to design novel peptide sequences with optimized antiviral activity and reduced cytotoxicity. These computational approaches can screen billions of candidate sequences in silico before synthesizing and testing the most promising candidates, dramatically accelerating the discovery pipeline compared to traditional screening of natural peptide libraries.

The integration of AI design with delivery platforms (nanoparticles, hydrogels, inhalable formulations) and combination therapy strategies (pairing AVPs with conventional antivirals or immunomodulators) represents the current frontier of the field.

What Broad-Spectrum Antiviral Peptides Cannot Do

Non-enveloped viruses remain largely untouchable. Membrane-disrupting peptides are ineffective against viruses that lack lipid envelopes, including norovirus, rotavirus, poliovirus, and adenovirus. These viruses have protein capsids that resist amphiphilic peptide insertion. Immune-modulating peptides like LL-37 may have indirect activity against non-enveloped viruses through interferon stimulation, but this is a host-mediated rather than virus-targeted effect.

Selectivity remains the primary barrier. A peptide that disrupts viral membranes will also, at sufficient concentration, disrupt host cell membranes. The therapeutic window (the ratio between effective antiviral concentration and cytotoxic concentration) is often narrow. Melittin exemplifies this problem: potent antiviral activity accompanied by potent host cell toxicity. Engineering selectivity through charge modifications, amphiphilicity tuning, and structural constraints (cyclization, stapling) is an active area of research but has not produced a clinically approved broad-spectrum AVP.

Systemic delivery is problematic. Peptides are degraded rapidly by proteases in blood, cleared quickly by the kidneys, and may trigger immune responses at therapeutic doses. Local delivery (intranasal, topical, nebulized) circumvents many of these problems but limits treatment to accessible infection sites.

One approval in 25+ years. Despite thousands of publications and hundreds of characterized antiviral peptides, enfuvirtide remains the only FDA-approved antiviral peptide (2003), and it is specific to HIV-1 rather than broad-spectrum. The translation gap from in vitro activity to clinical efficacy is wide.

The Bottom Line

Broad-spectrum antiviral peptides exploit conserved structural features of viruses, particularly lipid membrane envelopes and fusion machinery, to inhibit diverse pathogens with a single compound. Membrane-disrupting peptides like cecropin A and melittin show cross-family activity against unrelated viruses. Fusion inhibitors like EK1C4 achieve nanomolar potency against both coronaviruses and HIV. LL-37 combines receptor blocking, membrane disruption, and immune modulation. The field has advanced in delivery (intranasal, nebulized) and design (AI-driven, structure-guided dual-mechanism). The selectivity problem, separating antiviral activity from host cell toxicity, remains the primary barrier to clinical translation beyond the single approved peptide, enfuvirtide.

Frequently Asked Questions

What are broad-spectrum antiviral peptides?

Broad-spectrum antiviral peptides are short protein fragments that inhibit multiple virus types through shared mechanisms rather than targeting specific viral proteins. They primarily work by disrupting viral lipid envelopes, blocking virus-cell fusion, occluding receptor-binding sites, or enhancing host immune responses. Peptides like EK1C4 have shown activity against both coronaviruses and HIV, while cationic peptides like cecropin A inhibit both arenaviruses and herpesviruses (Albiol Matanic et al., 2004).

How do antiviral peptides destroy viruses?

The primary mechanism is membrane disruption: cationic amphiphilic peptides insert into the lipid bilayer envelope of viruses, creating pores that physically destroy the virus before it contacts host cells. This works against any enveloped virus (influenza, HIV, coronaviruses, herpes, dengue) but not non-enveloped viruses. Fusion inhibitor peptides like EK1C4 block the conformational changes viruses need to merge with host cell membranes, achieving IC50 values as low as 1.3 nM against SARS-CoV-2 (Xia et al., 2020).

Can viruses become resistant to antiviral peptides?

The theoretical resistance barrier is higher than for conventional antivirals because viruses cannot mutate their lipid membrane composition as readily as surface proteins. However, resistance is not impossible: some organisms can alter membrane fluidity or charge to reduce peptide binding. Limited experimental data exists on viral resistance to antiviral peptides specifically (Kiran et al., 2025). Dual-mechanism peptides that combine membrane disruption with protein binding provide two independent barriers to resistance development.

Is there an FDA-approved antiviral peptide?

Yes, enfuvirtide (brand name Fuzeon), approved in 2003 for HIV-1. It works by blocking the HIV gp41-mediated membrane fusion step. Enfuvirtide is virus-specific (HIV-1 only), not broad-spectrum. No broad-spectrum antiviral peptide has received FDA approval. Despite decades of research, the translation gap from laboratory activity to clinical drug remains the field's central challenge.

Does LL-37 have antiviral properties?

Yes, in laboratory studies. LL-37, the only human cathelicidin antimicrobial peptide, binds the SARS-CoV-2 spike protein and blocks ACE2 receptor binding (Roth et al., 2025). It also increases interferon-beta production during rhinovirus infection (Cerps et al., 2025), demonstrating dual antiviral mechanisms: direct receptor blocking and indirect immune enhancement. LL-37 production is regulated by vitamin D levels, linking sun exposure to innate antiviral defense.

Why are antiviral peptides not widely used as drugs?

Three main barriers limit clinical adoption. First, selectivity: peptides that disrupt viral membranes also damage host cell membranes at similar concentrations, creating narrow therapeutic windows. Second, stability: peptides degrade rapidly in blood and are cleared quickly by the kidneys. Third, delivery: systemic administration is inefficient, though intranasal and nebulized delivery are showing promise for respiratory infections (Wang et al., 2026). Only one antiviral peptide (enfuvirtide) has been FDA-approved in over 25 years of research.